https://scholars.lib.ntu.edu.tw/handle/123456789/484105
標題: | Survival of patients with small cell lung carcinoma in Taiwan | 作者: | Kuo Y.-H. ZHONG-ZHE LIN Yang Y.-Y. YU-YUN SHAO Shau W.-Y. Kuo R.N.C. CHIH-HSIN YANG Lai M.-S. |
公開日期: | 2012 | 卷: | 82 | 期: | 1 | 起(迄)頁: | 19-24 | 來源出版物: | Oncology | 摘要: | Background: Small cell lung cancer (SCLC) is the most aggressive form of lung cancer. The prognosis for SCLC patients remains unsatisfactory despite advances in chemotherapy. In this study, we sought to clarify the prognosis and treatment patterns of patients with SCLC. Methods: A cohort comprising all patients diagnosed with SCLC between January 2004 and December 2006 was assembled from the Taiwan Cancer Database. Patients were followed up until December 31, 2009, to determine overall survival. Patient survival was estimated using the Kaplan-Meier method, and Cox's proportional hazard model was used to determine the relationship between prognostic factors and median survival time. Results: Among the 1,684 patients diagnosed with SCLC, 1,215 (72%) were diagnosed with extensive-stage disease and 469 (28%) with limited-stage disease. Most of the patients were male (90%). The median survival duration of patients with limited-stage and extensive-stage SCLC was 10.3 months and 5.6 months, respectively. For limited-stage patients, surgery, chemotherapy, and combined chemotherapy and radiotherapy resulted in better survival than best supportive care (HR 0.20, p < 0.001; HR 0.61, p < 0.001, and HR 0.37, p < 0.001, respectively). For extensive-stage patients, male gender was significantly associated with a poor prognosis (HR 1.45, p < 0.001) and chemotherapy was shown to improve overall survival more effectively than best supportive care (HR 0.37, p < 0.001). Conclusion: For limited-stage SCLC patients, surgery, chemotherapy, and combined chemotherapy and radiotherapy improved survival compared to best supportive care. Extensive-stage SCLC patients benefited more from chemotherapy treatment than from best supportive care. Copyright ? 2012 S. Karger AG, Basel. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84862785781&doi=10.1159%2f000335084&partnerID=40&md5=d79f1821143c142840e6989963519fdc https://scholars.lib.ntu.edu.tw/handle/123456789/484105 |
ISSN: | 0030-2414 | DOI: | 10.1159/000335084 | SDG/關鍵字: | antineoplastic agent; adult; aged; article; cancer chemotherapy; cancer diagnosis; cancer patient; cancer prognosis; cancer radiotherapy; cancer surgery; cancer survival; cohort analysis; controlled study; female; follow up; hazard ratio; human; Kaplan Meier method; lung small cell cancer; major clinical study; male; multimodality cancer therapy; overall survival; patient care; priority journal; proportional hazards model; Taiwan; Adolescent; Adult; Aged; Cohort Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Proportional Hazards Models; Small Cell Lung Carcinoma; Taiwan; Treatment Outcome |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。